Orforglipron maintains weight loss after injectable GLP-1 in the ATTAIN-MAINTAIN trial

TL;DR

Eli Lilly is running the ATTAIN-MAINTAIN Phase 3 trial to test whether orforglipron - the first approved non-peptide oral GLP-1 agonist, now marketed as Foundayo - can maintain the weight loss patients achieve on injectable GLP-1 medications like Ozempic, Wegovy, or Zepbound. The trial directly addresses one of the most pressing clinical and insurance questions in obesity medicine: can a cheaper daily pill substitute for expensive weekly injections and prevent the rebound weight gain that occurs when GLP-1 therapy stops?

In late 2025, the FDA approved orforglipron (Foundayo) - a once-daily pill that became the first non-peptide small-molecule GLP-1 receptor agonist approved for weight management and type 2 diabetes. Unlike semaglutide and tirzepatide, which are peptide-based and require injection (or in semaglutide's case, a complex large oral capsule with restricted dosing conditions), orforglipron is a true small molecule that can be swallowed as a simple pill with or without food.

Why ATTAIN-MAINTAIN matters so much

The rebound problem with GLP-1 medications is well-documented. When patients stop taking injectable GLP-1 therapy, they regain a substantial portion of lost weight - typically 50-65% within one to two years. This creates a dilemma: GLP-1 medications need to be taken indefinitely to maintain their effects, but injectable therapy is expensive (list price above $1,000 per month), faces insurance prior-authorisation hurdles, requires refrigeration, and involves weekly injections that not all patients tolerate long-term.

If an oral pill could maintain the weight loss achieved by a course of injectable therapy - even at somewhat lower efficacy - the implications for patients and healthcare systems are enormous. Orforglipron at its maximum approved dose produces approximately 7-9% weight loss over 36-40 weeks. Semaglutide (Wegovy) and tirzepatide (Zepbound) produce 15-22% at longer durations. The gap in weight loss efficacy is real. But the question ATTAIN-MAINTAIN asks is a different one: not which drug produces more weight loss from baseline, but whether orforglipron can sustain a weight already achieved by a more potent injectable - functioning as a lower-cost maintenance therapy.

The ATTAIN-MAINTAIN trial design

ATTAIN-MAINTAIN enrolls adults with obesity who have already achieved meaningful weight loss on injectable GLP-1 therapy (semaglutide or tirzepatide). After establishing their reduced weight on the injectable, participants are randomised to either:

• Continue on orforglipron (daily pill) to maintain their weight loss
• Switch to placebo (simulating stopping GLP-1 therapy entirely)

The primary endpoint is the percentage of weight regained or maintained over the maintenance period. The trial is designed to demonstrate whether the oral pill can prevent the rebound that otherwise occurs when patients stop injectables - or whether it can at least significantly blunt that rebound compared to no therapy at all.

Who this trial is designed for

The practical population this trial represents is large. Many patients start on injectable GLP-1 medications through employer-sponsored insurance that may be cancelled, lapse, or change. Others achieve their weight loss goal and want to de-escalate to a lower-cost maintenance option. Some patients struggle with weekly injections long-term and would prefer a daily pill. For all of these patients, the question ATTAIN-MAINTAIN is answering - can an oral GLP-1 pill maintain what an injectable GLP-1 achieved? - is exactly the right question.

The insurance dimension: a drug that could change coverage decisions

Foundayo (orforglipron) entered the market in late 2025 at a significantly lower price point than injectable GLP-1 medications. Eli Lilly listed it below $500 per month, and several insurers moved quickly to cover it as a preferred obesity treatment where injectable alternatives faced restrictions. The ATTAIN-MAINTAIN trial has direct implications for insurance coverage policy:

• If the trial shows orforglipron successfully maintains injectable-achieved weight loss, insurers may implement step-therapy protocols requiring patients to try orforglipron before approving the more expensive injectables
• If orforglipron proves effective for maintenance, insurers may cover it for patients who have cycled off injectables due to cost or supply issues
• A positive result would strengthen the clinical rationale for coverage of all oral GLP-1 options as first-line maintenance therapy

From a healthcare economics perspective, the value of a weight maintenance drug is enormous. Obesity costs the US healthcare system an estimated $1.72 trillion annually in direct and indirect costs. An oral maintenance therapy at half the cost of injectable GLP-1s - if clinically effective - could change the cost-effectiveness calculus significantly.

What "stopping Ozempic weight regain" searches are really asking

One of the most-searched phrases in GLP-1 medicine in 2025-2026 is some variant of "stopping Ozempic weight regain" or "how to keep weight off after GLP-1." These searches reflect a real clinical need. ATTAIN-MAINTAIN is one of the most direct research responses to that need. While results are not yet published, the design of the trial - switching from injectable to oral rather than stopping cold - represents exactly the maintenance strategy that is clinically intuitive but has lacked trial evidence.

What orforglipron users need to know about nutrition

Whether patients use orforglipron for initial weight loss or as a maintenance therapy after injectables, the nutritional risks are the same as the broader GLP-1 class. Appetite suppression reduces food intake and with it the intake of essential micronutrients. Foundayo (orforglipron) is a newer approval and does not yet have long-term nutritional outcome data, but the mechanism - sustained GLP-1 receptor agonism suppressing appetite - is identical to injectables. The same B12, vitamin D, iron, magnesium, and zinc deficiency risks apply. GLP-1 Shield is formulated for the entire class - not just injectables - and is relevant from day one of any GLP-1 therapy, oral or injectable.

Frequently asked questions

What is the ATTAIN-MAINTAIN trial testing?

ATTAIN-MAINTAIN is an Eli Lilly Phase 3 trial testing whether orforglipron (Foundayo) - once-daily oral GLP-1 pill - can maintain weight loss achieved on injectable GLP-1 medications (semaglutide or tirzepatide). Patients who have lost weight on an injectable are switched to either orforglipron or placebo, and the trial measures how much weight is maintained versus regained over the maintenance period.

Can you switch from Ozempic or Wegovy to an oral GLP-1 pill?

Switching from injectable to oral GLP-1 is clinically plausible and is what ATTAIN-MAINTAIN is studying. Orforglipron acts on the same GLP-1 receptor as semaglutide and tirzepatide, though with somewhat lower maximum efficacy at standard doses. Whether the oral pill provides enough receptor activation to maintain the weight set point established by injectable therapy is the trial's central question - results are not yet published.

How much weight do you gain back when you stop Ozempic?

Multiple studies show patients regain 50-65% of their lost weight within one to two years of stopping injectable GLP-1 therapy. A 2022 STEP 1 extension study found patients who stopped semaglutide after 68 weeks had regained two-thirds of their lost weight by week 120. This rebound occurs because the weight set point is maintained partly by biological appetite signals that return when the GLP-1 receptor is no longer activated.

Is orforglipron (Foundayo) covered by insurance?

Coverage varies by insurer and plan. Foundayo entered the market in late 2025 at a lower price point than injectable GLP-1s, and several insurers adopted it as a preferred obesity medication. Some plans that previously did not cover injectable GLP-1s for obesity have covered Foundayo. Coverage decisions are evolving rapidly and depend on your specific plan - contacting your insurer directly is the most reliable way to determine your coverage.